Merck: COVID-19 oral antiviral drug reduces risk of death
The pharma firm reports molnupiravir was shown to cut risk of hospitalization or death by 50% compared to placebos in a positive interim Phase III analysis.
Source: outsourcing-pharma.com
Page 47 - Linical Evolution News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Linical Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Linical Evolution Today - Breaking & Trending Today
Uniting research, healthcare can benefit both: Biofourmis
An executive from the digital therapeutics specialist discusses the clinical trial landscape, and how clinical care can yield a number of important benefits.
Source: outsourcing-pharma.com
Study examines long-term effects of COVID-19 on athletes
The Heart of Athletes study, using Deloitte’s ConvergeHealth MyPath for Clinical platform, aims to examine heart inflammation in athletes with the virus.
Source: outsourcing-pharma.com
BioCelerate, FDA forge nonclinical data partnership
The two organizations have formed a public-private partnership aimed at improving nonclinical research through better practices and standardization.
Source: outsourcing-pharma.com
Dutch biotech seeks out industry alliances to commercialize its ADC on back of trial results
Dutch biotech, Byondis, today announced positive topline results from a Phase 3 study, which it says confirms the safety and efficacy of its antibody drug conjugate (ADC) - SYD985 - as a treatment for patients with pretreated HER2-positive locally advanced or metastatic breast cancer (MBC).
Source: outsourcing-pharma.com